N Quispe1, L Asencios1, C Obregon1, G E Velásquez2, C D Mitnick3, M Lindeborg4, H Jave5, L Solari6. 1. Instituto Nacional de Salud, Lima, Peru. 2. Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA. 3. Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, Division of Global Health Equity, Brigham and Women's Hospital, Boston, MA, Partners In Health, Boston, MA. 4. Harvard Medical School, Boston, MA, USA. 5. Hospital Nacional Dos de Mayo, Lima. 6. Instituto Nacional de Salud, Lima, Peru, Escuela de Medicina, Universidad Peruana de Ciencias Aplicadas, Lima, Peru.
Abstract
BACKGROUND: Peru has one of the highest burdens of multidrug-resistant tuberculosis (MDR-TB), but universal drug susceptibility testing (DST) has not yet been achieved. OBJECTIVE: To estimate the proportion of drug resistance among smear-positive TB patients in Peru. DESIGN: From September 2014 to March 2015, we performed a national drug resistance survey of patients aged ≥15 years; TB was diagnosed based on sputum smear positivity. We performed DST at the National Reference Laboratory of the Peruvian National Institute of Health, Lima, Peru, using the proportion method in Middlebrook 7H10 agar for four first-line drugs and six second-line drugs, and the Wayne method for pyrazinamide. RESULTS: Of the 1908 new and 272 previously treated patients included in the analysis, 638 (29.3%) patients had resistance to at least one first-line drug. MDR-TB was diagnosed in 7.3% of new and 16.2% of previously treated patients (P < 0.001). There were five (0.2%) patients with extensively drug-resistant TB. CONCLUSION: MDR-TB has increased to 7.3% in new patients from 5.3% in the previous survey, indicating that resistance to anti-tuberculosis drugs is increasing in Peru. Ongoing community transmission of resistant strains highlights an urgent need for early diagnosis, optimised treatment and effective contact tracing of MDR-TB patients.
BACKGROUND: Peru has one of the highest burdens of multidrug-resistant tuberculosis (MDR-TB), but universal drug susceptibility testing (DST) has not yet been achieved. OBJECTIVE: To estimate the proportion of drug resistance among smear-positive TBpatients in Peru. DESIGN: From September 2014 to March 2015, we performed a national drug resistance survey of patients aged ≥15 years; TB was diagnosed based on sputum smear positivity. We performed DST at the National Reference Laboratory of the Peruvian National Institute of Health, Lima, Peru, using the proportion method in Middlebrook 7H10 agar for four first-line drugs and six second-line drugs, and the Wayne method for pyrazinamide. RESULTS: Of the 1908 new and 272 previously treated patients included in the analysis, 638 (29.3%) patients had resistance to at least one first-line drug. MDR-TB was diagnosed in 7.3% of new and 16.2% of previously treated patients (P < 0.001). There were five (0.2%) patients with extensively drug-resistant TB. CONCLUSION: MDR-TB has increased to 7.3% in new patients from 5.3% in the previous survey, indicating that resistance to anti-tuberculosis drugs is increasing in Peru. Ongoing community transmission of resistant strains highlights an urgent need for early diagnosis, optimised treatment and effective contact tracing of MDR-TBpatients.
Authors: N S Gomathi; S M Devi; R Lakshmi; R Ramachandran; D F Wares; V Kumar; N Selvakumar Journal: Int J Tuberc Lung Dis Date: 2012-03-08 Impact factor: 2.373
Authors: Zully M Puyén; Joshi Acosta; George Obregon; Edson Pacheco; Hada Ramirez; Alberto Mendoza; Diana Marín; Anthony D Harries Journal: Rev Panam Salud Publica Date: 2016-01
Authors: G Canetti; W Fox; A Khomenko; H T Mahler; N K Menon; D A Mitchison; N Rist; N A Smelev Journal: Bull World Health Organ Date: 1969 Impact factor: 9.408
Authors: A R Escombe; L Huaroto; E Ticona; M Burgos; I Sanchez; L Carrasco; E Farfán; F Flores; D A J Moore Journal: Int J Tuberc Lung Dis Date: 2010-09 Impact factor: 2.373
Authors: H J Menzies; G Moalosi; V Anisimova; V Gammino; C Sentle; M A Bachhuber; E Bile; K Radisowa; O Kachuwaire; J Basotli; T Maribe; R Makombe; J Shepherd; B Kim; T Samandari; S El-Halabi; J Chirenda; K P Cain Journal: Int J Tuberc Lung Dis Date: 2014-09 Impact factor: 2.373
Authors: Larissa Otero; Fiorella Krapp; Cristina Tomatis; Carlos Zamudio; Francine Matthys; Eduardo Gotuzzo; Patrick Van der Stuyft; Carlos Seas Journal: PLoS One Date: 2011-10-27 Impact factor: 3.240
Authors: Sonya S Shin; Martin Yagui; Luis Ascencios; Gloria Yale; Carmen Suarez; Neyda Quispe; Cesar Bonilla; Joaquin Blaya; Allison Taylor; Carmen Contreras; Peter Cegielski Journal: Emerg Infect Dis Date: 2008-05 Impact factor: 6.883
Authors: J T Galea; D Puma; C Tzelios; H Valdivia; A K Millones; J Jiménez; M B Brooks; C M Yuen; L Lecca; M C Becerra; S Keshavjee Journal: Public Health Action Date: 2022-03-21